EPS for Cytosorbents Corporation (CTSO) Expected At $-0.13

October 14, 2018 - By Winifred Garcia

Cytosorbents Corporation (NASDAQ:CTSO) LogoInvestors sentiment increased to 3.85 in Q2 2018. Its up 1.49, from 2.36 in 2018Q1. It increased, as 8 investors sold Cytosorbents Corporation shares while 5 reduced holdings. 32 funds opened positions while 18 raised stakes. 14.51 million shares or 289.97% more from 3.72 million shares in 2018Q1 were reported.
Morgan Stanley holds 0% or 85,872 shares in its portfolio. Barclays Public Ltd Llc holds 0% or 2,305 shares. Strs Ohio invested in 8,300 shares or 0% of the stock. Jpmorgan Chase & Communications owns 197,580 shares for 0% of their portfolio. Parallax Volatility Advisers Lp has invested 0% in Cytosorbents Corporation (NASDAQ:CTSO). Pnc Financial Service Grp reported 20,500 shares stake. Deutsche Bankshares Ag reported 0% of its portfolio in Cytosorbents Corporation (NASDAQ:CTSO). Aqr Cap Mgmt Lc has invested 0% in Cytosorbents Corporation (NASDAQ:CTSO). Granite Ltd Limited Liability Company accumulated 58,851 shares. Raymond James Associates invested 0% in Cytosorbents Corporation (NASDAQ:CTSO). 4,235 were reported by Legal And General Group Inc Public Limited Com. Gp One Trading L P holds 10,221 shares or 0% of its portfolio. California State Teachers Retirement Sys has 43,452 shares for 0% of their portfolio. Bnp Paribas Arbitrage Sa reported 0% stake. Royal Bancorporation Of Canada owns 4,803 shares for 0% of their portfolio.

Since April 17, 2018, it had 0 insider purchases, and 10 selling transactions for $1.63 million activity. Chan Phillip P. sold $167,246 worth of stock or 11,418 shares. 10,000 Cytosorbents Corporation (NASDAQ:CTSO) shares with value of $85,000 were sold by BLOCH KATHLEEN P.. 26,000 shares valued at $376,282 were sold by Kraus Al on Thursday, August 30.

Analysts expect Cytosorbents Corporation (NASDAQ:CTSO) to report $-0.13 EPS on November, 8.They anticipate $0.06 EPS change or 85.71 % from last quarter’s $-0.07 EPS. After having $-0.19 EPS previously, Cytosorbents Corporation’s analysts see -31.58 % EPS growth. The stock increased 2.00% or $0.21 during the last trading session, reaching $10.72. About 189,241 shares traded. Cytosorbents Corporation (NASDAQ:CTSO) has risen 129.49% since October 14, 2017 and is uptrending. It has outperformed by 113.87% the S&P500.

CytoSorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its platform blood purification technology incorporating a proprietary adsorbent, porous polymer technology. The company has market cap of $337.25 million. The Company’s principal product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors. It currently has negative earnings. The firm also provides VetResQ device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.

Cytosorbents Corporation (NASDAQ:CTSO) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.